Clicks Group is undeniably a powerhouse on the JSE. It is widely recognised as a well-managed and resilient business. However, a persistent question dogs potential investors, particularly those inclined towards scepticism: is Clicks Group simply too expensive to justify buying? While it’s true that Clicks trades at a premium compared to many other retailers, this doesn’t automatically mean it’s never…
Tag: JSE
-
Aspen Pharmacare Manufacturing Dispute Shrouded in Mystery
ASPEN Pharmacare has issued a stark warning to investors. They are signalling a potential R2 billion plunge in core earnings for its 2025 financial year. This is due to the significant Aspen Pharmacare manufacturing dispute detailed this week. In a regulatory filing on Tuesday, Aspen alerted shareholders to emerging risks. It highlighted a “material contractual dispute” with an unnamed contract…
-
Clicks Interim Results Driven by Loyalty and Digital Sales
JSE-listed Clicks Group has released its Clicks interim results for the six months ending February 2025. They report impressive resilience and strategic accomplishments in the health and beauty retail sector. The group noted a 13.2% rise in headline earnings per share (HEPS). Clicks credits its robust earnings performance to several crucial factors. These include significant market share growth in its…
-
The Ascendis Health Turnaround: From Debt to Profitability
Ascendis Health was once a darling of the JSE. It was listed in 2013. Its aggressive global plan nearly led to collapse, but now The Ascendis Health Turnaround is aiming to rectify past mistakes. Excessive debt fueled the company’s strategy. The plan to create a health giant faltered. Acquisitions lacked synergy, and offshore assets underperformed. The massive debt burden proved…